SEC filing · 10-Q

Kestra Medical Technologies, Ltd.: Quarterly report

Kestra Medical Technologies reported higher revenue alongside an increased net loss for the quarter ended July 31, 2026.

Filed September 14, 2026 · period ended July 31, 2026

Mixed for the company

What the numbers say

Revenue rose 60% to $31M versus the same quarter last year (8.1% up on the previous quarter); operating margin widened from -149.1% to -121.6%; diluted EPS -$0.75 versus -$0.50; cash fell by $31.2M to $68.6M while debt rose by $29.8M; diluted share count up 14% (dilution).

Compared with the same period a year earlier, from the figures Kestra Medical Technologies, Ltd. reported to the SEC.

What happened

Revenue rose to $30,971 thousand for the three months ended July 31, 2026 compared to $19,371 thousand in the prior year period.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Kestra Medical Technologies, Ltd.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.